CA1333392CCA000616720ACA616720ACA1333392CCA 1333392 CCA1333392 CCA 1333392CCA 000616720 ACA000616720 ACA 000616720ACA 616720 ACA616720 ACA 616720ACA 1333392 CCA1333392 CCA 1333392C
Authority
CA
Canada
Prior art keywords
pharmaceutical formulation
ester
compound
formulation according
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878719877Aexternal-prioritypatent/GB8719877D0/en
Application filed by Wellcome Foundation LtdfiledCriticalWellcome Foundation Ltd
Application grantedgrantedCritical
Publication of CA1333392CpublicationCriticalpatent/CA1333392C/fr
Sels cristallins stables de monohydrate de 2',3'-didesoxyinosine, de monohydrate de 2',3'-didesoxy-2',3'-didehydrothymidine, et de hemihydrate de 2',3'-didesoxy-2'-fluoroinosine, hautement solubles dans l'eau et antiviraux